Biophytis (BPTSY) Competitors $2.00 0.00 (0.00%) As of 09/12/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock BPTSY vs. ATXI, LIPO, INDP, GTBP, SLRX, VRAX, GLMD, CANF, UPC, and ELABShould you be buying Biophytis stock or one of its competitors? The main competitors of Biophytis include Avenue Therapeutics (ATXI), Lipella Pharmaceuticals (LIPO), Indaptus Therapeutics (INDP), GT Biopharma (GTBP), Salarius Pharmaceuticals (SLRX), Virax Biolabs Group (VRAX), Galmed Pharmaceuticals (GLMD), Can-Fite BioPharma (CANF), Universe Pharmaceuticals (UPC), and PMGC (ELAB). These companies are all part of the "pharmaceutical products" industry. Biophytis vs. Its Competitors Avenue Therapeutics Lipella Pharmaceuticals Indaptus Therapeutics GT Biopharma Salarius Pharmaceuticals Virax Biolabs Group Galmed Pharmaceuticals Can-Fite BioPharma Universe Pharmaceuticals PMGC Avenue Therapeutics (NASDAQ:ATXI) and Biophytis (NASDAQ:BPTSY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends. Which has more risk and volatility, ATXI or BPTSY? Avenue Therapeutics has a beta of -0.07, meaning that its stock price is 107% less volatile than the S&P 500. Comparatively, Biophytis has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Which has stronger valuation & earnings, ATXI or BPTSY? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvenue TherapeuticsN/AN/A-$10.38M-$0.95-0.88BiophytisN/AN/A-$18.43MN/AN/A Do institutionals and insiders hold more shares of ATXI or BPTSY? 17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 0.1% of Biophytis shares are held by institutional investors. 1.8% of Avenue Therapeutics shares are held by insiders. Comparatively, 3.7% of Biophytis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor ATXI or BPTSY? In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Biophytis'average media sentiment score. Company Overall Sentiment Avenue Therapeutics Neutral Biophytis Neutral Is ATXI or BPTSY more profitable? Biophytis' return on equity of 0.00% beat Avenue Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avenue TherapeuticsN/A -471.57% -296.50% Biophytis N/A N/A N/A SummaryBiophytis beats Avenue Therapeutics on 4 of the 6 factors compared between the two stocks. Get Biophytis News Delivered to You Automatically Sign up to receive the latest news and ratings for BPTSY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BPTSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BPTSY vs. The Competition Export to ExcelMetricBiophytisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$702K$859.67M$5.75B$10.27BDividend YieldN/A4.84%5.72%4.60%P/E RatioN/A1.1874.9226.41Price / SalesN/A121.58457.0188.61Price / CashN/A19.5625.8129.91Price / Book-0.126.6713.256.28Net Income-$18.43M-$4.13M$3.29B$270.38M7 Day PerformanceN/A2.23%0.47%2.70%1 Month PerformanceN/A8.23%4.59%5.99%1 Year Performance-60.71%26.55%73.41%25.94% Biophytis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BPTSYBiophytisN/A$2.00flatN/AN/A$702KN/A0.0030ATXIAvenue Therapeutics1.2131 of 5 stars$0.86-3.3%N/A-70.8%$2.74MN/A0.054Gap DownLIPOLipella Pharmaceuticals2.1435 of 5 stars$0.59+1.7%N/A-80.2%$2.73M$536.36K-0.144News CoverageShort Interest ↓INDPIndaptus Therapeutics3.3715 of 5 stars$2.39-6.3%$238.00+9,858.2%-93.9%$2.65MN/A-0.066Short Interest ↓Gap DownGTBPGT Biopharma2.6648 of 5 stars$0.74-7.0%$11.00+1,378.5%-63.1%$2.65MN/A-0.188Short Interest ↓SLRXSalarius Pharmaceuticals0.2944 of 5 stars$5.18+13.1%N/A-77.4%$2.64MN/A-0.1220Short Interest ↑Gap UpVRAXVirax Biolabs Group2.2265 of 5 stars$0.57-2.6%$3.00+431.0%-77.0%$2.44M$10K0.005Positive NewsGLMDGalmed Pharmaceuticals0.9221 of 5 stars$1.45+2.8%N/A-63.3%$2.39MN/A-0.0920Positive NewsShort Interest ↑CANFCan-Fite BioPharma1.8977 of 5 stars$0.66+1.3%$14.50+2,083.7%-72.4%$2.35M$560K-0.378News CoverageShort Interest ↑UPCUniverse PharmaceuticalsN/A$4.08+6.3%N/A-98.8%$2.30M$19.29M0.00220Gap UpELABPMGC0.8496 of 5 stars$4.69+5.0%N/A-99.7%$1.97M$1.71M-0.0118Short Interest ↓ Related Companies and Tools Related Companies Avenue Therapeutics Alternatives Lipella Pharmaceuticals Alternatives Indaptus Therapeutics Alternatives GT Biopharma Alternatives Salarius Pharmaceuticals Alternatives Virax Biolabs Group Alternatives Galmed Pharmaceuticals Alternatives Can-Fite BioPharma Alternatives Universe Pharmaceuticals Alternatives PMGC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BPTSY) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biophytis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biophytis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BPTSY Stock Alerts